.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX04_Pegademase.Pegademase .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX04_Pegademase.Pegademase| name: | Pegademase | |
| ATC code: | L03AX04 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 0.21 | L |
| clearance: | 1.5 | ml/kg/h |
| other parameters in model implementation | ||
Pegademase (PEG-ADA) is a modified form of adenosine deaminase enzyme conjugated with polyethylene glycol to increase its stability and half-life. It has been used as enzyme replacement therapy for severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency. It is an FDA-approved orphan drug but less commonly used since the advent of stem cell and gene therapies.
Estimated pharmacokinetic parameters in ADA-SCID adult patients based on typical literature-reported dosing and known characteristics of PEGylated proteins. No published human pharmacokinetic data found for pegademase; values are approximated/extrapolated from available enzyme replacement therapy data.